|By Marketwired .||
|July 26, 2013 09:00 AM EDT||
SAN DIEGO, CA -- (Marketwired) -- 07/26/13 -- The OTC Journal, the longest running electronic newsletter focused on the small cap and microcap sectors, notes Nuvilex's (OTCQB: NVLX) efforts to study the potential applications of its proprietary encapsulation technology to enhance the efficacy of cannabidiol (CBD)-based cancer treatments may line up perfectly with the Medical Marijuana legalization movement in the US.
At present, Marijuana use is estimated at $54 billion in the US. It is legal for prescribed use in 18 states. Two states, Colorado and Washington, have legalized marijuana use for recreational purposes. The Justice Department has clearly stated a "no prosecutions" policy for prescribed medicinal use. No such statement has been forthcoming regarding recreational use, and interested parties are anxiously awaiting clarification from Attorney General Eric Holder.
The 2012 elections created a storm of interest in the sector when voters in Washington and Colorado legalized small amounts of marijuana for recreational use in their states. About 20 small public companies enjoyed major price and volume appreciation -- anywhere from 100% to 2500%.
5 states currently have pending legislation to legalize medicinal marijuana use: Illinois, Minnesota, New York, Ohio, and Pennsylvania. New Hampshire became the 19th to legalize physician prescribed Marijuana use this past week.
Two states have recently decriminalized the possession of small amounts: Texas and Vermont.
A comprehensive drug policy report, 400 pages in length, was released by the Organization of American States this past May. The report gave considerable weight to the legalization or de-penalizing of Marijuana. The report points out the US has spent many billions attempting to stop the flows of Marijuana with little effect.
Since Nuvilex (OTCQB: NVLX) completed a recent financing and procured the final global rights to the encapsulation technology for all cancer treatments, the company can now vigorously pursue its use with a Cannabinoid therapies that are growing in popularity for cancer treatment.
The coming 2013 elections are likely to bring new legalization initiatives and create a resurgence of interest in the stocks of Cannabis related companies.
Nuvilex (OTCQB: NVLX) shareholders could be positioned to benefit greatly as the company continues to explore this potential application for its technology.
For an archive of previous OTC Journal editions on Nuvilex (OTCQB: NVLX), visit the following URL:
Additional detail via the OTC Journal article as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.otcjournal.com.
About The OTC Journal: The OTC Journal is the longest running electronic newsletter committed to small and microcap stocks. Published continuously since 1998, the OTC Journal provides readers with short term trading ideas, long term ongoing coverage of worthy small and microcap companies, and overall market commentary.
The OTC Journal is also an investor relations firm that publishes a newsletter that provides a forum for issuers who wish to advertise their company. To read our publication, including information regarding our compensation, visit www.otcjournal.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.